

Table of Contents

Preface to the First Edition	xxvii
Preface to the Second Edition	xxxi
1. Overview of Hematopoietic Stem Cell Transplantation	1
<i>John R. Wingard, MD</i>	
I. Historical Perspective	1
II. A Primer of the Transplant Procedure	4
III. General Aspects About Different Types of HSCT	5
IV. What This Book Is About	8
2. Common Uses of Hematopoietic Stem Cell Transplantation.	9
<i>Joseph H. Antin, MD, and John R. Wingard, MD</i>	
I. Introduction	9
II. Marrow Failure	9
III. Hematologic Malignancies	14
IV. References/Suggested Readings	26
3. Hematopoietic Stem Cell Transplantation for Nonmalignant Disorders	29
<i>Shalini Shenoy, MD</i>	
I. Introduction	29
II. Marrow Failure Syndromes	30
III. Metabolic Disorders	32
IV. Immune Deficiency/Dysfunction Disorders	34
V. Hemoglobinopathies	37
VI. Miscellaneous Rare Genetic Disorders	39
VII. Summary	40
VIII. References/Suggested Readings	40
4. Patient Evaluation Before Transplantation (Adult)	43
<i>Jack W. Hsu, MD; Mehdi Hamadani, MD; and Steven M. Devine, MD</i>	
I. Introduction	43
II. Initial Consultation	44
III. Assessment of Disease Status	47
IV. Assessment of Physiologic Status	49
V. Psychological, Financial, and Caregiver Considerations	57
VI. References/Suggested Readings	57

5. Patient Evaluation Before Transplantation (Pediatric)	59
<i>Nancy A. Kernan, MD</i>	
I. Overview	59
II. Assessment at Time of Referral	60
III. Assessment of Disease Status	60
IV. Assessment of Physiologic Function	61
6. Venous Access for Hematopoietic Stem Cell Transplantation	
Patients	65
<i>James C. Andrews, MD, FSIR</i>	
I. General Principles	65
II. Options for Chronic Central Venous Access	72
III. Managing Central Venous Access Problems	74
IV. Summary	80
V. References/Suggested Readings	81
7. Conditioning Regimens	83
<i>Javier Bolaños-Meade, MD, and Richard J. Jones, MD</i>	
I. Introduction	83
II. Common Myeloablative Regimens	84
III. Common Nonmyeloablative/RIC	86
IV. Toxicities	86
V. Antiemetic Management	88
VI. Selecting the Optimal Regimen	88
VII. References/Suggested Readings	91
8. Hematopoietic Progenitor Cell Donor Evaluation	93
<i>John P. Miller, MD, PhD</i>	
I. Introduction	93
II. Types of Hematopoietic Progenitor Cell Donation	93
III. Medical Evaluation of HPC Donors	94
IV. Donor Consent for HPC Donation	102
V. Subsequent Donations	105
VI. Summary	106
VII. References/Suggested Readings	106
9. Optimal Donor Selection for Allogeneic Hematopoietic	
Stem Cell Transplantation.	109
<i>Aleksandr Lazaryan, MD, MPH, PhD, and Daniel J. Weisdorf, MD</i>	
I. Introduction	109
II. Related Donors	110
III. Adult Volunteer Unrelated Donors	113
IV. Umbilical Cord Blood	118

V.	Summary	126
VI.	References/Suggested Readings	126
10.	HLA	129
	<i>Effie W. Petersdorf, MD</i>	
I.	The Major Histocompatibility Complex	129
II.	HLA Typing in Support of Allogeneic Transplant Programs	135
III.	The Transplant Barrier	140
IV.	References/Suggested Readings	143
11.	HLA-Haploidentical Hematopoietic Stem Cell Transplantation	145
	<i>Christopher G. Kanakry, MD, and Ephraim J. Fuchs, MD, MBA</i>	
I.	HLA Transplantation	145
II.	Modern Approaches to HLA-Haploidentical Transplantation	147
III.	T-Cell-Replete HLA-Haploidentical HSCT	154
IV.	Reasons for Failure of HLA-Haploidentical HSCT	163
V.	Conclusion	164
VI.	References/Suggested Readings	164
12.	Pediatric Aspects of Hematopoietic Stem Cell Transplantation ...	167
	<i>Kimberly A. Kasow, DO, and Gregory A. Hale, MD</i>	
I.	Overview	167
II.	Malignant Indications for Allogeneic Transplantation	167
III.	Nonmalignant Indications for Transplantation	169
IV.	Indications for Autologous Transplantation	174
V.	Hematopoietic Stem Cell Sources	175
VI.	Cellular Therapies	176
VII.	Marrow Issues	176
VIII.	Apheresis Issues	176
IX.	Conditioning Regimen Issues	177
X.	Pharmaceutical Aspects	177
XI.	Acute and Chronic GVHD	178
XII.	Supportive Care Issues	178
XIII.	Prophylaxis	181
XIV.	Late Effects	181
XV.	References/Suggested Readings	185
	Appendix 12-1. Drug and Radiation Doses for Pediatric HSCT	187
13.	Stem Cell Grafts	191
	<i>Martin Körbling, MD, and Axel R. Zander, MD</i>	
I.	Introduction	191
II.	Biology of Cell Populations Contained in Hematopoietic Tissue-Derived Stem Cell Grafts	192

III.	Quantification of Graft-Containing Cells	194
IV.	Engraftment Potential.	195
V.	Choice of Stem Cell Source in Adult Transplantation	197
VI.	References/Suggested Readings	198
14.	Stem Cell Collection Techniques.	201
	<i>Ivana N.M. Micallef, MD, FRCP(C), and Dennis A. Gastineau, MD</i>	
I.	Marrow Harvesting.	201
II.	Peripheral Blood Stem Cell Mobilization	202
III.	Autologous Transplantation.	204
IV.	Allogeneic Transplantation	209
V.	References/Suggested Readings	210
15.	Cord Blood Graft Collection and Processing	213
	<i>Sue Armitage, BSc, and Elizabeth J. Shpall, MD</i>	
I.	Overview.	213
II.	Types of Cord Blood Banking	214
III.	Advantages of Cord Blood as a Source of Hematopoietic Stem Cells.	214
IV.	Disadvantages of Cord Blood as a Source of Hematopoietic Stem Cells.	215
V.	Cord Blood Banking Operations	215
VI.	Registration of Units.	220
VII.	Clinical Results of Cord Blood Transplantation	220
VIII.	References/Suggested Readings	223
16.	Laboratory Processing of Hematopoietic Progenitor Cells.	225
	<i>Dennis A. Gastineau, MD, and Douglas J. Padley, MT(ASCP)</i>	
I.	Introduction	225
II.	Manufacturing in the Cell Processing Laboratory	225
III.	Plasma or Red Cell Incompatibility	231
IV.	Donor Lymphocyte Infusion	234
V.	HPC Product Testing	235
VI.	Regulatory and Accreditation Issues and Process Control	235
VII.	Other Products and Product Manufacturing.	236
VIII.	Administration of HPC Products	237
IX.	References/Suggested Readings	237
17.	Hematopoietic Progenitor Cell Administration	239
	<i>Christopher A. Tormey, MD, and Edward L. Snyder, MD</i>	
I.	Introduction	239
II.	Overview of HPC Components	239
III.	Basics of HPC Administration	240
IV.	ABO and Rh Incompatibility	243

V.	Acute Adverse Events Associated with HPC Administration: Complications and Management244
VI.	References/Suggested Readings252
18.	Engraftment	255
	<i>Paul V. O'Donnell, MD, PhD, FACP</i>	
I.	Introduction255
II.	Factors Affecting Engraftment256
III.	Chimerism262
IV.	Erythroid Engraftment264
V.	Engraftment Following Allogeneic HSCT from Alternative Donors266
VI.	Engraftment Syndrome269
VII.	References/Suggested Readings271
19.	Immune Reconstitution	273
	<i>Anthony D. Sung, MD; Yubin Kang, MD; and Nelson J. Chao, MD, MBA</i>	
I.	Overview of the Human Immune System273
II.	Assays for Monitoring Immune Reconstitution275
III.	Immune Reconstitution276
IV.	Immunomodulation and Immunoenhancement285
V.	Conclusion286
VI.	References/Suggested Readings288
20.	Transfusion Support for Hematopoietic Stem Cell Transplantation	291
	<i>Erin K.G. Meyer, DO, MPH, and Zbigniew M. Szczepiorkowski, MD, PhD, FCAP</i>	
I.	Blood Component Collection and Testing291
II.	Blood Components—Types and Indications294
III.	Blood Components—Modifications301
IV.	Adverse Events Related to Transfusion of Blood Components303
V.	Transfusion Support for RBC-Incompatible Transplants303
VI.	Transfusion Support for the Pediatric HSCT Patient307
VII.	Therapeutic Apheresis308
VIII.	References/Suggested Readings313
21.	Hematopoietic Growth Factor Support After Hematopoietic Stem Cell Transplantation	315
	<i>Hong Yen Ng, Bsc (Pharm) (Hons), BCOP, and Yan Jun Lim, Bsc (Pharm) (Hons), M Clin Pharm, BCOP</i>	
I.	Red Cell Growth Factors315
II.	White Cell Growth Factors324

III.	Megakaryocytic Growth Factors	332
IV.	References/Suggested Readings	334
22.	Medical Nutrition Therapy in Hematopoietic Stem Cell Transplantation.	337
	<i>Alison Winter-Lai, MS, RD, CSO, CDN, and Courtney McGowan, MS, RD, CSO, CNSC, CDN</i>	
I.	Nutrition Assessment Before Hematopoietic Stem Cell Transplantation	337
II.	HSCT and Energy/Protein Needs in Adults	340
III.	HSCT and Energy/Protein Needs in Pediatrics	341
IV.	Maintenance Fluid Needs	341
V.	Vitamins/Minerals	342
VI.	Eating Problems During and After HSCT	344
VII.	Dietary Guidelines for Immunosuppressed Patients	344
VIII.	Nutrition Support	347
IX.	Long-term Nutrition Considerations Following HSCT	352
X.	Summary	352
XI.	References/Suggested Readings	353
23.	Fluids and Electrolyte Management.	355
	<i>Elizabeth C. DiMaggio, PharmD, BCOP</i>	
I.	Fluctuations During Peripheral Blood Stem Cell (PBSC) Apheresis	363
II.	Influence of Drug Therapy Prior to HSCT	364
III.	Electrolyte Abnormalities Following HSCT	365
IV.	Fluid and Electrolyte Fluctuations from Supportive Therapy Following HSCT.	366
V.	Electrolyte Disturbances at Engraftment	366
VI.	References/Suggested Readings	367
24.	Bacterial Infections	369
	<i>John R. Wingard, MD</i>	
I.	Introduction	369
II.	Risk Factors for Bacterial Infection	369
III.	Neutropenic Fever	369
IV.	Bacterial Infectious Syndromes	374
V.	Prophylaxis	377
VI.	References/Suggested Readings	377
25.	Viral Infections After Engraftment.	379
	<i>Helen Leather, BPharm, and Michael Boeckh, MD</i>	
I.	Herpes Viruses	379
II.	Respiratory Viruses	390

III.	Adenoviruses	396
IV.	Polyomaviruses	397
V.	References/Suggested Readings	399
26.	Fungal Infections	401
	<i>Shmuel Shoham, MD, and Kieren A. Marr, MD</i>	
I.	Epidemiology and Pathogenesis	401
II.	Prophylaxis	403
III.	Specific Infections	404
IV.	Summary	416
V.	References/Suggested Readings	416
27.	Infectious Hepatitis in Hematopoietic Stem Cell Transplantation	419
	<i>Richard A. Zuckerman, MD, MPH</i>	
I.	Introduction	419
II.	Pretransplant Evaluations	419
III.	Hepatitis A Virus	420
IV.	Hepatitis B Virus	421
V.	Hepatitis C Virus	425
VI.	Posttransplant Concerns	427
VII.	Peritransplant Immunization	434
VIII.	References/Suggested Readings	434
28.	Posttransplant Vaccination Strategies	437
	<i>Ernesto Ayala, MD, and Claudio Anasetti, MD</i>	
I.	Introduction	437
II.	General Concepts	437
III.	Vaccines Against Bacteria	438
IV.	Vaccines Against Viruses	442
V.	Serologic Testing	445
VI.	Donor Vaccination	445
VII.	Immunization of Family Members and Health-Care Workers	446
VIII.	References/Suggested Readings	446
29.	Liver Disease After Hematopoietic Stem Cell Transplantation	449
	<i>Jan S. Moreb, MD</i>	
I.	Introduction	449
II.	Liver Problems During Pretransplant Evaluation	450
III.	Drug-Induced Hepatobiliary Abnormalities Following HSCT	454
IV.	Nondrug-Related Liver Problems in the First 100 Days	458

V.	Liver Abnormalities Beyond Day 100	461
VI.	References/Suggested Readings	464
30.	Oral Complications in Hematopoietic Stem Cell Transplantation	465
	<i>Nathaniel S. Treister, DMD, DMSC, and Stephen T. Sonis, DMD, DMSC</i>	
I.	Introduction	465
II.	Pre-HSCT Dental Evaluation	465
III.	Approach to Diagnosis in the HSCT Recipient	468
IV.	Oral Mucositis	469
V.	Oral Infections	472
VI.	Noninfectious Causes of Orofacial Pain	475
VII.	Graft-vs-Host Disease	476
VIII.	Second Malignancy	480
IX.	References/Suggested Readings	480
31.	Gastrointestinal Complications of Hematopoietic Stem Cell Transplantation	481
	<i>Judith Lees, BPharm, and Dorothy M. Keefe, MD</i>	
I.	Introduction	481
II.	Nausea and Vomiting	482
II.	Delayed Nausea or Vomiting Prevention	486
III.	Esophageal/Gastric Mucositis	486
IV.	Small Intestinal/Colonic Mucositis and Diarrhea	486
V.	Constipation	490
VI.	References/Suggested Readings	490
32.	Lung Injury Following Hematopoietic Stem Cell Transplantation	493
	<i>Kenneth R. Cooke, MD, and Gregory A. Yanik, MD</i>	
I.	Introduction	493
II.	Infectious Interstitial Pneumonias	493
III.	Idiopathic Pneumonia Syndrome	496
IV.	Chronic Pulmonary Dysfunction After HSCT	505
V.	Conclusion	511
VI.	References/Suggested Readings	512
33.	Management of Pain in the Hematopoietic Stem Cell Transplantation Patient	513
	<i>Laura E. Wiggins, PharmD, BCOP</i>	
I.	Overview	513
II.	Pathophysiology of Pain	513
III.	Types of Pain in the HSCT Patient	514
IV.	Diagnosis of Pain	517

IV.	Management of Pain	517
V.	Summary	526
VI.	References/Suggested Readings	526
34.	Hemorrhagic Cystitis	529
	<i>Zuzana Potáčová, MD, PhD; Tina Dalianis, MD, PhD;</i>	
	<i>Katarina Le Blanc, MD, PhD; and Olle Ringdén, MD, PhD</i>	
I.	Overview	529
II.	Pathogenesis and Role of Infection	532
III.	Management	534
IV.	References/Suggested Readings	537
35.	Management of Coagulopathies/Transplant-Associated Microangiopathy	539
	<i>Yan Yun Wu, MD, PhD, and Peter W. Marks, MD, PhD</i>	
I.	Hemorrhagic Complications	539
II.	Thrombotic Complications	544
III.	References/Suggested Readings	548
36.	Anticoagulation, Thrombosis, and Bleeding in the Hematopoietic Stem Cell Transplantation Patient	551
	<i>Marc S. Zumberg, MD, and Molly Mandernach, MD, MPH</i>	
I.	Introduction	551
II.	Bleeding Complications After HSCT	552
III.	Thrombotic Complications After HSCT	554
IV.	Balancing the Risks of Bleeding vs the Benefits of Anticoagulation	556
V.	Anticoagulant Choice During HSCT	561
VI.	References/Suggested Readings	565
37.	Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation	567
	<i>Bradley W. Blaser, MD, PhD; Vincent T. Ho, MD; and Robert J. Soiffer, MD</i>	
I.	Management of Hyperlipidemia Before Engraftment	567
II.	Management of Hyperlipidemia After Engraftment	568
III.	References/Suggested Readings	574
38.	Neurologic Complications in Hematopoietic Stem Cell Transplantation	577
	<i>Maxim Norkin, MD, PhD</i>	
I.	Introduction	577
II.	Neurologic Complications During the Pretransplant Period	577

III.	Neurologic Complications During Preengraftment	579
IV.	Neurologic Complications After Reconstitution of Marrow Function	593
V.	References/Suggested Reading	596
39.	Acute GVHD	597
	<i>Corey Cutler, MD, MPH, FRCP(C)</i>	
I.	Acute GVHD Pathobiology and Risk Factors	597
II.	GVHD Prophylaxis	599
III.	Diagnosis, Epidemiology, and Clinical Manifestations of Acute GVHD	602
IV.	Treatment and Outcome of Acute GVHD	606
V.	Survival After Acute GVHD	609
VI.	References/Suggested Readings	609
40.	Chronic GVHD	611
	<i>Iskra Pusic, MD; Georgia B. Vogelsang, MD; and Steven Z. Pavletic, MD</i>	
I.	Pathophysiology of Chronic GVHD	612
II.	Risk Factors	612
III.	Diagnosis	612
IV.	Classification	613
V.	Staging	617
VI.	Clinical Manifestations	618
VII.	GVT Effect	622
VIII.	Prevention	622
IX.	Treatment	622
X.	Measuring the Response to Therapy	628
XI.	Monitoring Patients with Chronic GVHD	628
XII.	Prognosis of Chronic GVHD	628
XIII.	References/Suggested Readings	630
41.	Photopheresis	631
	<i>Joseph G. Sokhn, MD; Jaehyuk Choi, MD, PhD; and Francine M. Foss, MD</i>	
I.	Introduction	631
II.	Collection Techniques	631
III.	UVA Irradiation	634
IV.	Mechanisms of ECP	636
V.	Therapeutic Applications of Photopheresis	638
VI.	Clinical Efficacy of ECP for Treatment of GVHD	639
VII.	Summary	643
VIII.	References/Suggested Readings	643

42. Late Complications: Screening and Management	647
<i>Navneet S. Majhail, MD, MS, and J. Douglas Rizzo, MD, MS</i>	
I. Overview	647
II. Guidelines for Screening/Prevention of Late Complications	647
III. Neuropsychiatric Complications	648
IV. Ocular Complications	648
V. Oral Complications	656
VI. Respiratory Complications	656
VII. Cardiac and Vascular Complications	657
VIII. Liver Complications	657
IX. Renal and Genitourinary Complications	658
X. Complications of Muscle and Connective Tissue	658
XI. Skeletal Complications	659
XII. Nervous System Complications	659
XIII. Endocrine Complications	660
XIV. Mucocutaneous Complications	660
XV. Fertility	661
XVI. General Preventive Health	661
XVII. References/Suggested Readings	661
43. Neuropsychiatric Complications of Hematopoietic Stem Cell Transplantation	663
<i>Mitchell R. Levy, MD, and Jesse R. Fann, MD, MPH</i>	
I. General Principles of Assessment and Management	663
II. Level of Distress	668
III. Severe Neuropsychiatric Complications	678
IV. Cancer-Related Fatigue	679
V. Somatization	680
VI. Survivorship	681
VII. References/Suggested Readings	682
44. Psychosocial Sequelae of Hematopoietic Stem Cell Transplantation in Survivors and Caregivers	685
<i>Michelle M. Bishop, PhD</i>	
I. Introduction	685
II. Major Psychosocial Sequelae After HSCT	686
III. Family Caregivers	701
IV. References/Suggested Readings	703
45. Second Cancers	705
<i>Smita Bhatia, MD, MPH</i>	
I. Overview	705
II. Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Autologous HSCT	706

III.	Donor-Derived Hematologic Malignancies After HSCT	711
IV.	Lymphomas	711
V.	Solid Tumors	713
VI.	Conclusions	715
VII.	References/Suggested Readings	717
46.	Relapse After Hematopoietic Stem Cell Transplantation	719
	<i>Michael R. Bishop, MD</i>	
I.	Introduction	719
II.	Biology	720
III.	Relapse Risk	720
IV.	Monitoring	721
V.	Prevention of Relapse	722
VI.	Treatment of Relapse	722
VII.	Summary	727
VIII.	References/Suggested Readings	729
47.	Donor Lymphocyte Infusion and Graft-vs-Leukemia	
	Effects of Allogeneic Transplantation	733
	<i>Hans-Jochem Kolb, MD, and Raymund Buhmann, MD</i>	
I.	Separation of GVL Effects and Graft-vs-Host Disease	736
II.	CML	738
III.	DLI in AML and MDS	741
IV.	DLI in ALL	744
V.	DLI in Chronic Lymphocytic Leukemia and Lymphoma	744
VI.	DLI in Multiple Myeloma	745
VII.	DLI in Solid Tumors	745
VIII.	Immunotherapy in Patients with HLA-Haploidentical Donors	746
IX.	Treatment of Viral Infections with Donor Lymphocytes	746
X.	Do Donor Lymphocytes Eliminate Leukemia Stem Cells?	747
XI.	Failure of Durable Control—Immune Escape Mechanisms	747
XII.	Future of DLI	749
XIII.	Acknowledgments	749
XIV.	References/Suggested Readings	749
48.	Gynecologic Management of Fertility	751
	<i>Sanaz Ghazal, MD; Jason G. Bromer, MD; and</i>	
	<i>Pasquale Patrizio, MD, MBE</i>	
I.	Introduction	751
II.	The Effect of Gonadotoxic Agents on Fertility	752
III.	Established Strategies for Fertility Preservation	753
IV.	Experimental Strategies for Fertility Preservation	756
V.	Strategies for Ovarian Protection	759
VI.	Ethical Considerations in Fertility Preservation	760

VII.	Summary and Conclusions	760
VIII.	References/Suggested Readings	763
49.	Pathogenesis, Diagnosis, and Management of Iron Overload in Hematopoietic Stem Cell Transplantation.	765
	<i>Maxim Norkin, MD, PhD, and Ashley Richards, PharmD, BCOP</i>	
I.	Introduction	765
II.	Basic Principles of Iron Homeostasis and Pathophysiology of IO in HSCT Recipients	765
III.	Assessment and Monitoring of IO and Body Iron Burden.	766
IV.	Prevalence of IO in HSCT Recipients	770
V.	Impact of IO on Clinical Outcomes in HSCT Recipients	772
VI.	Iron Reduction Therapy in HSCT Recipients	774
VII.	Screening for IO After HSCT	779
VIII.	Monitoring the Response to IRT	779
IX.	Summary and Future Developments.	780
X.	References/Suggested Readings.	780
50.	Dosing Considerations in Overweight and Obese Patients Receiving High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation.	783
	<i>Dennis L. Cooper, MD</i>	
I.	Overview	783
II.	Dosing for Overweight Patients	784
III.	References/Suggested Readings	787
51.	Common Procedures in Hematopoietic Stem Cell Transplantation	789
	<i>Bimalangshu R. Dey, MD, PhD, and Thomas R. Spitzer, MD</i>	
I.	Introduction	789
II.	Marrow Aspiration and Biopsy	789
III.	Skin Biopsy	791
IV.	Lumbar Puncture	792
V.	Marrow Harvest	795
VI.	Apheresis	797
VII.	References/Suggested Readings	802
52.	Data Collection and Management for Hematopoietic Stem Cell Transplantation Centers	805
	<i>Wael Saber, MD, MS, and Mary M. Horowitz, MD, MS</i>	
I.	Introduction—Why Collect Data?	805
II.	Data Collection at the Transplant Center—Ensuring Quality and Addressing Local Research Needs.	806

III.	Outcomes Registries—Contributing to the National and International Research Enterprise	807
IV.	Addressing Federal Requirements—the US SCTOD	813
V.	Summary	817
VI.	References/Suggested Readings	817
53.	Accreditation Standards and Quality Programs in Hematopoietic Stem Cell Transplantation.	819
	<i>Michele W. Sugrue, MS, MT(ASCP)SBB;</i>	
	<i>Zbigniew M. Szczepiorkowski, MD, PhD; and</i>	
	<i>Dennis A. Gastineau, MD</i>	
I.	Quality Management Systems in Clinical Practice	819
II.	Change Control	824
III.	The Quality Committee	824
IV.	Interruption of Services	824
V.	Accreditation and Standards	825
VI.	United States Food and Drug Administration (FDA) Regulations and Oversight	832
VII.	Conclusion	835
VIII.	References/Suggested Readings	836
54.	Financial Aspects of Hematopoietic Stem Cell Transplantation.	837
	<i>Richard T. Maziarz, MD; Jeffrey W. Chell, MD; and</i>	
	<i>Richard E. Champlin, MD</i>	
I.	Introduction	837
II.	Increase in Utilization and Impact of HSCT on National Health-Care Costs	838
III.	Complexity of Care Increases Costs	840
IV.	Payer Source	841
V.	Contracts and Reimbursement Strategies	843
VI.	Resource Utilization	844
VII.	Research	846
VIII.	Quality	848
IX.	Future Considerations	848
X.	Summary	849
XI.	References/Suggested Readings	851
Appendices		
	Appendix 1. Antibacterial Adult Dosage Guidelines for Patients with Normal Renal Function and Renal Insufficiency (As of January 2013)	853
	Appendix 2. Antifungal Adult Dosage Guidelines for Patients with Normal Renal Function and Renal Insufficiency (As of January 2013)	873

Appendix 3. Antiviral Adult Dosage Guidelines for Renal Insufficiency (as of January 2013)	879
Appendix 4. Drug Interactions with Antifungal Agents Cytochrome P450 Isoenzymes Involved in Drug Metabolism	885
Appendix 5. Clinically Relevant Pharmacokinetic Drug Interactions with Ketoconazole	889
Appendix 6. Clinically Relevant Pharmacokinetic Drug Interactions with Fluconazole	893
Appendix 7. Clinically Relevant Pharmacokinetic Drug Interactions with Itraconazole	895
Appendix 8. Clinically Relevant Pharmacokinetic Drug Interactions with Voriconazole: Effect of Voriconazole on the Pharmacokinetics of Other Drugs	899
Appendix 9. Clinically Relevant Pharmacokinetic Drug Interactions with Voriconazole: Effect of Other Drugs on the Pharmacokinetics of Voriconazole	905
Appendix 10. Drug Interactions with Posaconazole	907
Appendix 11. Clinically Relevant Pharmacokinetic Drug Interactions with Tacrolimus	911
Appendix 12. Clinically Relevant Pharmacokinetic Drug Interactions with Cyclosporine	915
Appendix 13. Clinically Relevant Pharmacokinetic Drug Interactions with Sirolimus	919
Appendix 14. Cyclosporine Dosing and Monitoring Guidelines	923
Appendix 15. Tacrolimus Dosing and Monitoring Guidelines	925
Index	929

Bonus References Are Located on USB Flash Card

